Cibc Asset Management Inc Exelixis, Inc. Transaction History

Cibc Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $172,268 - $215,939	8,949 New	8,949 $214,000
Q2 2022 Aug 09, 2022	SELL	$17.44 - $23.16 $16,201 - $21,515	-929 Reduced 6.82%	12,693 $264,000
Q4 2021 Feb 08, 2022	BUY	$15.84 - $21.88 $13,606 - $18,794	859 Added 6.73%	13,622 $249,000
Q3 2021 Nov 09, 2021	BUY	$16.3 - $21.14 $19,625 - $25,452	1,204 Added 10.42%	12,763 $270,000
Q1 2021 May 14, 2021	SELL	$20.53 - $25.22 $2,094 - $2,572	-102 Reduced 0.87%	11,559 $261,000
Q3 2020 Nov 05, 2020	BUY	$20.67 - $26.94 $5,973 - $7,785	289 Added 2.54%	11,661 $285,000
Q4 2019 Feb 14, 2020	BUY	$15.15 - $18.89 $12,120 - $15,112	800 Added 7.57%	11,372 $200,000
Q2 2018 Aug 09, 2018	BUY	$18.56 - $22.45 $13,585 - $16,433	732 Added 7.44%	10,572 $228,000
Q3 2017 Nov 06, 2017	BUY	$23.35 - $29.24 $229,764 - $287,721	9,840	9,840 $238,000

460

240M

2.04M

1.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $8.35B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Cibc Asset Management Inc with notifications on news.